IN8bio's Glioblastoma Therapy Extends Survival to Over 19.5 Months, Nearly Doubling Standard of Care
Summary
IN8bio presented updated clinical data for its DeltEx DRI therapy in newly diagnosed glioblastoma at ASCO 2026, showing median overall survival exceeding 19.5 months, a 48% improvement over standard of care. Median progression-free survival also nearly doubled to 13.0 months. This positive clinical development is critical for the company, which has recently disclosed a going concern warning, a limited cash runway, and initiated a $2.8 million at-the-market offering to secure funding. Strong clinical data in a devastating cancer like glioblastoma is essential for IN8bio's future financing and valuation.
At the time of this announcement, INAB was trading at $1.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.4M. The 52-week trading range was $1.17 to $5.61. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.